Xu R - Search Results

1

TRIM29 overexpression is associated with poor prognosis and promotes tumor progression by activating Wnt/β-catenin pathway in cervical cancer.

Xu R, Hu J, Zhang T, Jiang C, Wang HY. Xu R, et al. Oncotarget. 2016 May 10;7(19):28579-91. doi: 10.18632/oncotarget.8686. Oncotarget. 2016. PMID: 27081037 Free PMC article.

2

Caveolin-1, a stress-related oncotarget, in drug resistance.

Wang Z, Wang N, Liu P, Peng F, Tang H, Chen Q, Xu R, Dai Y, Lin Y, Xie X, Peng C, Situ H. Wang Z, et al. Among authors: xu r. Oncotarget. 2015 Nov 10;6(35):37135-50. doi: 10.18632/oncotarget.5789. Oncotarget. 2015. PMID: 26431273 Free PMC article. Review.

3

Identification of microRNA-615-3p as a novel tumor suppressor in non-small cell lung cancer.

Pu HY, Xu R, Zhang MY, Yuan LJ, Hu JY, Huang GL, Wang HY. Pu HY, et al. Among authors: xu r. Oncol Lett. 2017 Apr;13(4):2403-2410. doi: 10.3892/ol.2017.5684. Epub 2017 Feb 7. Oncol Lett. 2017. PMID: 28454411 Free PMC article.

4

p53R2 overexpression in cervical cancer promotes AKT signaling and EMT, and is correlated with tumor progression, metastasis and poor prognosis.

Jiang C, Xu R, Li XX, Wang YY, Liang WQ, Zeng JD, Zhang SS, Xu XY, Yang Y, Zhang MY, Wang HY, Zheng XFS. Jiang C, et al. Among authors: xu xy, xu r. Cell Cycle. 2017 Sep 17;16(18):1673-1682. doi: 10.1080/15384101.2017.1320629. Epub 2017 Aug 25. Cell Cycle. 2017. PMID: 28841361 Free PMC article.

5

A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry.

Guo Q, Chen K, Lin X, Su Y, Xu R, Dai Y, Qiu C, Song X, Mao S, Chen Q. Guo Q, et al. Among authors: xu r. Oncotarget. 2017 Jul 17;8(55):93492-93501. doi: 10.18632/oncotarget.19313. eCollection 2017 Nov 7. Oncotarget. 2017. PMID: 29212167 Free PMC article.

6

INHBA upregulation correlates with poorer prognosis in patients with esophageal squamous cell carcinoma.

Lyu S, Jiang C, Xu R, Huang Y, Yan S. Lyu S, et al. Among authors: xu r. Cancer Manag Res. 2018 Jun 18;10:1585-1596. doi: 10.2147/CMAR.S160186. eCollection 2018. Cancer Manag Res. 2018. PMID: 29950896 Free PMC article.

7

CHP2 Promotes Cell Proliferation in Breast Cancer via Suppression of FOXO3a.

Zhao X, Xie T, Dai T, Zhao W, Li J, Xu R, Jiang C, Li P, Deng J, Su X, Ma N. Zhao X, et al. Among authors: xu r. Mol Cancer Res. 2018 Oct;16(10):1512-1522. doi: 10.1158/1541-7786.MCR-18-0157. Epub 2018 Jul 2. Mol Cancer Res. 2018. PMID: 29967111

8

High CEP55 expression is associated with poor prognosis in non-small-cell lung cancer.

Jiang C, Zhang Y, Li Y, Lu J, Huang Q, Xu R, Feng Y, Yan S. Jiang C, et al. Among authors: xu r. Onco Targets Ther. 2018 Aug 17;11:4979-4990. doi: 10.2147/OTT.S165750. eCollection 2018. Onco Targets Ther. 2018. PMID: 30154666 Free PMC article.

9

Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma.

Jiang C, Xu R, Li XX, Zhou YF, Xu XY, Yang Y, Wang HY, Zheng XFS. Jiang C, et al. Among authors: xu xy, xu r. Mol Cancer Ther. 2018 Dec;17(12):2610-2621. doi: 10.1158/1535-7163.MCT-17-0541. Epub 2018 Sep 17. Mol Cancer Ther. 2018. PMID: 30224431 Free PMC article.

10

LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling.

Liu J, Xu R, Mai SJ, Ma YS, Zhang MY, Cao PS, Weng NQ, Wang RQ, Cao D, Wei W, Guo RP, Zhang YJ, Xu L, Chen MS, Zhang HZ, Huang L, Fu D, Wang HY. Liu J, et al. Among authors: xu l, xu r. Theranostics. 2020 Jun 12;10(17):7527-7544. doi: 10.7150/thno.45989. eCollection 2020. Theranostics. 2020. PMID: 32685003 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12,331 results

Search Page

Filters